Pulmocide presented two posters at the IDweek 2016, held October 26 – 30, 2016 in New Orleans, LA. These are as follows:
 
Anti-viral activities of PC786, a novel inhibitor of respiratory syncytial virus L-protein polymerase
PC786 is a novel anti-viral polymerase inhibitor designed for inhalation treatment of respiratory syncytial virus (RSV) infection. In this study, the in vitro profiles of PC786 were investigated againstRSV A and RSV B, including clinical isolates.

 

 

in vivo biomarker analysis of Intranasally Dosed PC945, a novel antifungal agent, in Aspergillus fumigatus infection in immunocompromised mice 
PC945 is a novel antifungal agent developed as an inhalation therapy for the treatment of lung aspergillosis. In this study, we examined the effects of intranasally dosed PC945 on fungus and cytokine biomarkers in Aspergillus fumigatus infected immunocompromised mice.